Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Licogliflozin - Novartis Pharmaceuticals

Drug Profile

Licogliflozin - Novartis Pharmaceuticals

Alternative Names: LIK-066

Latest Information Update: 03 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antifibrotics; Antihyperglycaemics; Dioxins; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Small molecules
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Discontinued Heart failure; Obesity; Polycystic ovary syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 03 Jan 2024 Novartis Pharmaceuticals terminates the phase II ELIVATE trial in Non-alcoholic steatohepatitis (Monotherapy, Combination therapy) in Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, Estonia, Germany, India, Italy, Japan, Mexico, Puerto Rico, Russia, Singapore, South Africa, South Korea, Spain, Taiwan, Turkey, United Kingdom and USA, due to the sponsor decision (PO, Capsule) (EudraCT2019-002324-32) (JapicCTI205173) (NCT04065841)
  • 02 Jan 2023 Licogliflozin is still in phase II trial for Hepatic fibrosis (Combination therapy) in the USA, Argentina, Belgium, Brazil, Bulgaria, Canada, China, Chile, Colombia, Estonia, Denmark, Germany, India, Israel, Italy, Japan, South Korea, Mexico, Puerto Rico, Russia, Singapore, Saudi Arabia, Slovakia, South Africa, Spain, Taiwan, Turkey, United Kingdom (NCT04065841) (EudraCT2019-002324-32)
  • 02 Jan 2023 Licogliflozin is still in phase II trial for Hepatic fibrosis (Monotherapy) in the USA, Argentina, Belgium, Brazil, Bulgaria, Canada, China, Chile, Colombia, Estonia, Denmark, Germany, India, Israel, Italy, Japan, South Korea, Mexico, Puerto Rico, Russia, Singapore, Saudi Arabia, Slovakia, South Africa, Spain, Taiwan, Turkey, United Kingdom (NCT04065841) (EudraCT2019-002324-32)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top